Holen Sie sich die Stockscreener-App
47.51
1.23%
-0.59
Handel nachbörslich:
47.51
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$48.10
Offen:
$47.23
24-Stunden-Volumen:
2.47M
Relative Volume:
1.36
Marktkapitalisierung:
$8.31B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
50.54
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
-9.57%
1M Leistung:
-21.61%
6M Leistung:
-32.48%
1J Leistung:
-23.52%
1-Tages-Spanne:
$46.01
$47.77
1-Wochen-Bereich:
$46.01
$53.00
52-Wochen-Spanne:
$46.01
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
47.51 | 8.31B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Former Novartis Deal Chief Who Led 50+ Strategic Transactions Joins OmniAb Board - Stock Titan
Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $95, Keeps Outperform Rating - marketscreener.com
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu - MSN
Bio-Techne Sets Date for Q3 2025 Financial Results: Key Details for Investors - Stock Titan
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Bio-Techne (TECH) Faces Downgrade Amid NIH Funding Concerns - GuruFocus
Forecasting The Future: 6 Analyst Projections For Bio-Techne - Benzinga
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Bio-Techne stock downgraded at KeyBanc (TECH:NASDAQ) - Seeking Alpha
KeyBanc Downgrades Bio-Techne to Sector Weight From Overweight - MarketScreener
KeyBanc cuts Bio-Techne stock rating on funding concerns By Investing.com - Investing.com India
KeyBanc cuts Bio-Techne stock rating on funding concerns - Investing.com
Trading (TECH) With Integrated Risk Controls - news.stocktradersdaily.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Techne Corp stock hits 52-week low at $56.58 amid market shifts - Investing.com
Bio-Techne Expands Collaboration With Leica To Enhance Spatial Multiomics Research Capabilities - Nasdaq
Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument - PR Newswire
Evercore ISI Adjusts Bio-Techne Price Target to $70 From $75, Maintains Outperform Rating - marketscreener.com
Is Bio-Techne Corporation Stock Underperforming the S&P 500? - Nasdaq
Is Bio-Techne Corporation Stock Underperforming The S&P 500? - Barchart.com
Exosomes Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne, QIAGEN, Lonza - openPR.com
Bio-Techne Opens New Customer Experience Centre in Germany - Nasdaq
3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Yahoo Finance
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Research Tools & Consumables Stocks Q4 Earnings: Bio-Techne (NASDAQ:TECH) Best of the Bunch - Yahoo Finance
Bio-Techne to Open New Customer Facility in Germany - Marketscreener.com
Bio-Techne's New Tech Hub Targets Major European Life Sciences Growth - Stock Titan
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting - Quantisnow
Game-Changing Cancer Detection Technology: RNAscope Shows Superior Results in Multiple Tumors - Stock Titan
Bio-Techne Earnings Preview: What to Expect - MSN
Evercore ISI Group Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation - MSN
Evercore ISI sets Bio-Techne stock Outperform with $75 target By Investing.com - Investing.com South Africa
6 Analysts Assess Bio-Techne: What You Need To Know - Benzinga
Evercore ISI sets Bio-Techne stock Outperform with $75 target - Investing.com
Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future - TipRanks
Bio-Techne (NASDAQ:TECH) shareholders have earned a 8.3% CAGR over the last five years - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Downgraded by StockNews.com to "Hold" - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Receives $82.14 Consensus Price Target from Analysts - Defense World
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Bio Techne at Barclays Conference: Strategic Growth Amid Market Challenges - Investing.com
TECH Stock Might Rise Following the Leo Shipping Announcement - Nasdaq
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Bio-Techne at Leerink’s Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts By Investing.com - Investing.com South Africa
GC Wealth Management RIA LLC Takes $805,000 Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne Begins Shipping LeoA Next Generation High-Throughput Simple Western System - Quantisnow
Bio-Techne launches high-throughput Leo System - Investing.com
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):